Evaluation of docetaxel- and oxaliplatin-based adjuvant chemotherapy in postgastrectomy gastric cancer patients reveals obvious survival benefits in docetaxel-treated mixed signet ring cell carcinoma patients

详细信息    查看全文

• 作者：Li Chen (1)
  Yan Shi (1)
  Jing Yuan (2)
  Qian Wu (1)
  Yalin Han (1)
  Rui Qin (1)
  Baoqing Jia (3)
  Bo Wei (4)
  Lixin Wei (2)
  Guanghai Dai (1)
  Shunchang Jiao (5)
  
• 关键词：Signet ring cell carcinoma ; Gastric adenocarcinoma ; Adjuvant chemotherapy ; Prognosis ; Survival
• 刊名：Medical Oncology
• 出版年：2014
• 出版时间：September 2014
• 年：2014
• 卷：31
• 期：9
• 全文大小：1,139 KB
• 参考文献：1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-0. CrossRef
  2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-0. CrossRef
  3. Fernández-Fernández FJ, Sesma P. Gastric cancer. Lancet. 2009;374:1594. CrossRef
  4. Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729-7. CrossRef
  5. Zhu X, Li J. Gastric carcinoma in China: current status and future perspectives. Oncol Lett. 2010;1:407-2. CrossRef
  6. Sobin LH, Gospodarowicz MK, Wittekind C. International Union Against Cancer (UICC) TNM classification of malignant tumours. 7th ed. New York: Wiley-Liss; 2004. p. 73-.
  7. Sobin LH, Compton CC. TNM seventh edition: what’s new, what’s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010;116:5336-. CrossRef
  8. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810-0. CrossRef
  9. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315-1. CrossRef
  10. Chae S, Lee A, Lee JH. The effectiveness of the new (7th) UICC N classification in the prognosis evaluation of gastric cancer patients: a comparative study between the 5th/6th and 7th UICC N classification. Gastric Cancer. 2011;14:166-1. CrossRef
  11. Hass HG, Smith U, J?ger C, et al. Signet ring cell carcinoma of the stomach is significantly associated with poor prognosis and diffuse gastric cancer (Lauren’s): single-center experience of 160 cases. Onkologie. 2011;34:682-. CrossRef
  12. Borch K, J?nsson B, Tarpila E, et al. Changing pattern of histological type, location, stage and outcome of surgical treatment of gastric carcinoma. Br J Surg. 2000;87:618-6. CrossRef
  13. Sidoni A. Differential trends in the intestinal and diffuse types of gastric carcinoma. Arch Pathol Lab Med. 2005;129:290.
  14. Huh CW, Jung DH, Kim JH, et al. Signet ring cell mixed histology may show more aggressive behavior than other histologies in early gastric cancer. J Surg Oncol. 2013;107:124-. CrossRef
  15. Yang XF, Yang L, Mao XY, Wu DY, Zhang SM, Xin Y. Pathobiological behavior and molecular mechanism of signet ring cell carcinoma and mucinous adenocarcinoma of the stomach: a comparative study. World J Gastroenterol. 2004;10:750-.
  16. Eckardt JR. Antitumor activity of docetaxel. Am J Health Syst Pharm. 1997;54:S2-.
  17. Hill BT, Whelan RD, Shellard SA, McClean S, Hosking LK. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs. 1994;12:169-2. CrossRef
  18. Armand JP. Focus on cellular pharmacology of docetaxel. Bull Cancer. 2003;90:1067-0.
  19. Schwartz GK, Winter K, Minsky BD, et al. Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). J Clin Oncol. 2009;27:1956-2. CrossRef
  
• 作者单位：Li Chen (1)
  Yan Shi (1)
  Jing Yuan (2)
  Qian Wu (1)
  Yalin Han (1)
  Rui Qin (1)
  Baoqing Jia (3)
  Bo Wei (4)
  Lixin Wei (2)
  Guanghai Dai (1)
  Shunchang Jiao (5)
  
  1. Department of Comprehensive Treatment Oncology, Chinese People’s Liberation Army General Hospital, Beijing, China
  2. Department of Pathology, Chinese People’s Liberation Army General Hospital, Beijing, China
  3. Department of Surgical Oncology, Chinese People’s Liberation Army General Hospital, Beijing, China
  4. Department of General Surgery, Chinese People’s Liberation Army General Hospital, Beijing, China
  5. Department of Medical Oncology, Chinese People’s Liberation Army General Hospital, No. 28 Fuxing Road, Beijing, 100853, China
  
• ISSN：1559-131X

文摘

The purpose of this study was to determine the disease-free and overall survival (DFS and OS, respectively) in 991 postgastrectomy gastric cancer patients untreated (n?=?372) or treated with either oxaliplatin-based (n?=?376) or docetaxel-based (n?=?243) chemotherapy and to identify prognostic factors that could help establish subgroups of patients who would benefit from such treatment. The median follow-up duration was 55.3?months (range 31.2-0.8?months). Subgroup analyses revealed that gastric adenocarcinoma (DFS 56.9 vs 53.2?months, P?=?0.180, χ2?=?1.802; OS not reached vs 70.7?months, P?=?0.521, χ2?=?0.412), but not absolute signet ring cell (SRC) carcinoma (DFS 15.1/18.0 vs 10.1?months, P?=?0.171/0.259, χ2?=?1.874/1.275; OS 21.0/26.1 vs 20.5?months, P?=?0.551/0.196, χ2?=?0.355/1.674), patients undergoing either docetaxel- or oxaliplatin-based chemotherapy had a lower risk of recurrence and increased survival in comparison to those without chemotherapy. In the mixed SRC carcinoma patients, DFS and OS of patients treated with docetaxel-based regimen had a longer survival (DFS 50.1 vs 29.9?months, P?=?0.046, χ2?=?3.987; OS not reached vs 48.6?months, P?=?0.016, χ2?=?5.854) and lower risk of recurrence and death (DFS HR 0.540, 95?% CI 0.355-.874, P?=?0.012; OS HR 0.452, 95?% CI 0.259-.790, P?=?0.005) than oxaliplatin-based chemotherapy. Cumulatively, our results indicate that adjuvant chemotherapy is beneficial and that docetaxel-based regimen should be considered for patients with mixed SRC carcinoma.